| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/18/2012 | CN101428053B 王不留行有效组分及其制备方法与用途 Vaccaria effective ingredients and preparation method and uses |
| 04/18/2012 | CN101428043B 诃子有效组分及其制备方法与用途 Terminalia effective ingredients and preparation method and uses |
| 04/18/2012 | CN101417934B 分离自牛樟芝萃取物的化合物 Isolated compound since Antrodia extract |
| 04/18/2012 | CN101411725B 一种提高免疫功能的海洋生物药 A way to improve immune function in marine biological drugs |
| 04/18/2012 | CN101390979B 枳椇子提取物及其制备方法与在制备抗肿瘤药物中的应用 Hovenia extract and its preparation method and application in the preparation of antineoplastic |
| 04/18/2012 | CN101367834B 用于制备醇和酚的水溶性膦酰氧基甲基衍生物的方法 A water-soluble phosphine acyloxymethyl derivatives of alcohols and phenols used in the preparation of |
| 04/18/2012 | CN101362719B 喹啉类衍生物以及包含其的组合物 Quinoline derivatives and compositions containing them |
| 04/18/2012 | CN101289477B 一种n-苯丙烯酰基壳寡糖及其制备 One kind n- benzene and preparation acryloyl Oligochitosan |
| 04/18/2012 | CN101177414B 抗癌化合物zd1839的新晶形、其制备方法及含该晶形的药用组合物 The new crystalline form of the anticancer compound zd1839, its preparation method and a pharmaceutical composition containing the crystalline form of |
| 04/17/2012 | US8160821 Method for supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs and a device for supporting a diagnosis for an effect of a treatment by using anthracycline anticancer drugs |
| 04/17/2012 | US8158750 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| 04/17/2012 | US8158647 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| 04/17/2012 | US8158624 Purine PI3K inhibitor compounds and methods of use |
| 04/17/2012 | US8158594 CYP1B1 nucleic acids and methods of use |
| 04/17/2012 | US8158592 for treatment of atopic conditions (dermatitis, allergies); point mutations; immunotherapy |
| 04/17/2012 | US8158585 Controlling extracellular protein degradation and/or clearance via modulation of tissue plasminogen activator activity; treating diabetic, autoimmune, cardiovascular, blood and nervous system disorders |
| 04/17/2012 | US8158385 Cell death-inducing agent |
| 04/17/2012 | CA2599328C Quinazoline derivative having tyrosine kinase inhibitory activity |
| 04/17/2012 | CA2593428C Pyrrolopyrazoles, potent kinase inhibitors |
| 04/17/2012 | CA2570307C Alpha-amino acid derivatives with antiinflammatory activity |
| 04/17/2012 | CA2566380C Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor |
| 04/17/2012 | CA2515384C Medicament for inhibiting tumour growth |
| 04/17/2012 | CA2513717C Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same |
| 04/17/2012 | CA2493843C Azolidinone-vinyl fused-benzene derivatives |
| 04/17/2012 | CA2483826C Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 04/17/2012 | CA2481521C Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| 04/17/2012 | CA2474104C N-oxides of n-phenyl-2-pyrimidine-amine derivatives |
| 04/17/2012 | CA2467110C Inclusion complex of paclitaxel with 2-hydroxypropyl-beta-cyclodextrin |
| 04/17/2012 | CA2410526C Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 04/17/2012 | CA2377607C Neurotrophic factor receptor |
| 04/17/2012 | CA2372181C Adjuvant combination formulations |
| 04/17/2012 | CA2371625C Polyamines and their use in therapy |
| 04/17/2012 | CA2363958C Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 04/17/2012 | CA2355495C Method of modulating tumor immunity |
| 04/17/2012 | CA2347928C Cell surface molecule-induced macrophage activation |
| 04/17/2012 | CA2145778C Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| 04/12/2012 | WO2012048259A2 Substituted pyridazine carboxamide compounds |
| 04/12/2012 | WO2012048258A2 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
| 04/12/2012 | WO2012048190A1 Annexin ii compositions and methods |
| 04/12/2012 | WO2012048129A2 Inhibitors of polo-like kinase |
| 04/12/2012 | WO2012047930A2 Compositions and methods for treatment of gynecologic cancers |
| 04/12/2012 | WO2012047775A1 Pharmaceutical combinations |
| 04/12/2012 | WO2012047699A1 Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
| 04/12/2012 | WO2012047317A2 Tumor specific antibodies and uses therefor |
| 04/12/2012 | WO2012047225A2 Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors |
| 04/12/2012 | WO2012047172A1 Picropodophyllin monohydrate or polymorph a in cancer therapy |
| 04/12/2012 | WO2012047171A1 Picropodophyllin polymorphs b or c for use in cancer therapy |
| 04/12/2012 | WO2012047017A2 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same |
| 04/12/2012 | WO2012046943A2 Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence |
| 04/12/2012 | WO2012046874A1 Method for evaluating degree of cancerization |
| 04/12/2012 | WO2012046873A1 Method for evaluating degree of cancerization |
| 04/12/2012 | WO2012046872A1 Method for evaluating degree of cancerization |
| 04/12/2012 | WO2012046871A1 Method for evaluating degree of cancerization |
| 04/12/2012 | WO2012046825A1 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
| 04/12/2012 | WO2012046797A1 Cancer stem cell mass and process for production thereof |
| 04/12/2012 | WO2012046745A1 Therapeutic agent for malignant tumors expressing mhc class ii |
| 04/12/2012 | WO2012046730A1 Method for activating helper t cell |
| 04/12/2012 | WO2012046681A1 Agent for inhibiting expression of lipid metabolism related mrna |
| 04/12/2012 | WO2012046260A1 Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours |
| 04/12/2012 | WO2012046062A1 Use of prodrugs to avoid gi mediated adverse events |
| 04/12/2012 | WO2012045999A1 Phosphoramidite derivatives of gemcitabine for use in the treatment cancer |
| 04/12/2012 | WO2012045883A1 Cyclopropylamine inhibitors of oxidases |
| 04/12/2012 | WO2012045734A1 Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides |
| 04/12/2012 | WO2012045437A1 Methods for tumor treatment and adipogenesis differentiation |
| 04/12/2012 | WO2012045274A1 Moesin modulators and uses thereof |
| 04/12/2012 | WO2012045237A1 Hsp90 inhibitor, preparation method and use thereof |
| 04/12/2012 | WO2012045196A1 Phosphoglycerate kinase inhibitors |
| 04/12/2012 | WO2012045195A1 Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| 04/12/2012 | WO2012045194A1 Benzodiazepinones as fak inhibitors for treatment of cancer |
| 04/12/2012 | WO2012045157A1 Arih2 regulates dendritic cell activation and autoimmunity |
| 04/12/2012 | WO2012045150A1 Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer |
| 04/12/2012 | WO2012045114A1 Agents and methods for treating hematologic conditions |
| 04/12/2012 | WO2012020123A3 Neuropilin as a biomarker for bevacizumab combination therapies |
| 04/12/2012 | WO2012018801A9 Suppressing bone loss with anti-il-19 antibody |
| 04/12/2012 | WO2012006275A9 Treating non-hematopoietic cancer with interleukin 6 |
| 04/12/2012 | WO2012006032A9 Treatment of blood cancer |
| 04/12/2012 | WO2012003421A9 Combinational compositions and methods for treatment of cancer |
| 04/12/2012 | WO2011160136A3 Progesterone containing oral dosage forms and related methods |
| 04/12/2012 | WO2011159685A3 Inhibition of wdr5 interaction with its binding partners and therapeutic methods |
| 04/12/2012 | WO2011152884A9 14 gene signature distinguishes between multiple myeloma subtypes |
| 04/12/2012 | WO2011150082A9 Methods of utilizing the arrestin-2/stam-1 complex as a therapeutic target |
| 04/12/2012 | WO2011150022A3 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| 04/12/2012 | WO2011133424A3 Genetic amplification of iqgap1 in cancer |
| 04/12/2012 | WO2011133210A3 A method treating breast cancer |
| 04/12/2012 | WO2011133039A3 Novel conjugates of cc-1065 analogs and bifunctional linkers |
| 04/12/2012 | WO2011127291A3 Compositions and methods for the treatment of a neoplasia |
| 04/12/2012 | WO2011077245A3 Composition comprising an oxysterol modulator and a cd25 - depleting monoclonal antibody for treating cancer |
| 04/12/2012 | WO2011041920A8 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing |
| 04/12/2012 | US20120089541 Biomarkers and methods of treatment |
| 04/12/2012 | US20120088827 Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB) |
| 04/12/2012 | US20120088825 Compounds with activity at estrogen receptors |
| 04/12/2012 | US20120088817 Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| 04/12/2012 | US20120088816 Head-And-Neck Tumor Proliferation Inhibitor |
| 04/12/2012 | US20120088811 Method for the treatment of acute myeloid leukemia |
| 04/12/2012 | US20120088810 Thioxanthone ring system derivatives |
| 04/12/2012 | US20120088807 Interlaced method for treating cancer or a precancerous condition |
| 04/12/2012 | US20120088799 Serotonin reuptake inhibitors |
| 04/12/2012 | US20120088797 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
| 04/12/2012 | US20120088784 Substituted Aromatic Compounds and Pharmaceutical Uses thereof |
| 04/12/2012 | US20120088783 Chroman derivatives |